Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis

Journal of Biological Chemistry

Volumn 289, Issue 52, 2014, Pages 36303-36314

  Homer Bouthiette, Collin ^a   Doetschman, Thomas ^b   Xiao, Liping ^a   Hurley, Marja M ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIALS; BODY FLUIDS; CELL CULTURE; COLLAGEN; COMPUTERIZED TOMOGRAPHY; GENE EXPRESSION; MAMMALS; MOLECULAR WEIGHT; MUSCULOSKELETAL SYSTEM; PHOSPHATASES;

ALKALINE PHOSPHATASE; BIOLOGICAL FUNCTIONS; BONE MARROW STROMAL CELLS; FIBROBLAST GROWTH FACTOR 2; HIGH MOLECULAR WEIGHT; MICROCOMPUTED TOMOGRAPHY; OSTEOBLAST DIFFERENTIATION; PARATHYROID HORMONES;

BONE;

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; ISOPROTEIN; MESSENGER RNA; PARATHYROID HORMONE; PHOSPHATE; SCLEROSTIN; ALKALINE PHOSPHATASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MARROW CELL; BONE METABOLISM; BONE MINERALIZATION; CONNECTIVE TISSUE; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DUAL ENERGY X RAY ABSORPTIOMETRY; FGF2 GENE; FGF23 GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC ASSOCIATION; IN VITRO STUDY; MARKER GENE; METABOLIC BALANCE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR WEIGHT; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PARATHYROID HORMONE BLOOD LEVEL; PERIOSTEUM; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POROSITY; SOST GENE; STROMA CELL; TRABECULAR BONE; 129 MOUSE; ANIMAL; BONE; CELL CULTURE; ENZYMOLOGY; GENETICS; HOMEOSTASIS; KNOCKOUT MOUSE; MALE; METABOLISM; OSTEOBLAST;

MUS;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DENSITY; BONE MARROW CELLS; CELLS, CULTURED; FIBROBLAST GROWTH FACTOR 2; HOMEOSTASIS; MALE; MICE, 129 STRAIN; MICE, KNOCKOUT; MOLECULAR WEIGHT; OSTEOBLASTS; PHOSPHATES; PROTEIN ISOFORMS;

EID: 84919808112     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.619569     Document Type: Article

References (45)

1. Gospodarowicz, D. (1990) Fibroblast growth factor. Chemical structure and biologic function. Clin. Orthop. Relat. Res. 257, 231-248
2. Arnaud, E., Touriol, C., Boutonnet, C., Gensac, M. C., Vagner, S., Prats, H., and Prats, A. C. (1999) A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol. Cell. Biol. 19, 505-514
3. Okada-Ban, M., Thiery, J. P., and Jouanneau, J. (2000) Fibroblast growth factor-2. Int. J. Biochem. Cell. Biol. 32, 263-267
4. Prats, H., Kaghad, M., Prats, A. C., Klagsbrun, M., Lélias, J. M., Liauzun, P., Chalon, P., Tauber, J. P., Amalric, F., and Smith, J. A. (1989) High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc. Natl. Acad. Sci. U.S.A. 86, 1836-1840
5. Sørensen, V., Nilsen, T., and Wiedlł ocha, A. (2006) Functional diversity of FGF-2 isoforms by intracellular sorting. BioEssays 28, 504-514
6. Coffin, J. D., Florkiewicz, R. Z., Neumann, J., Mort-Hopkins, T., Dorn, G. W., 2nd, Lightfoot, P., German, R., Howles, P. N., Kier, A., and O'Toole, B. A. (1995) Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6, 1861-1873
7. Sobue, T., Naganawa, T., Xiao, L., Okada, Y., Tanaka, Y., Ito, M., Okimoto, N., Nakamura, T., Coffin, J. D., and Hurley, M. M. (2005) Overexpression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J. Cell. Biochem. 95, 83-94
8. Xiao, L., Liu, P., Li, X., Doetschman, T., Coffin, J. D., Drissi, H., and Hurley, M. M. (2009) Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J. Biol. Chem. 284, 3170-3182
9. Delrieu, I. (2000) The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett. 468, 6-10
10. Xiao, L., Naganawa, T., Lorenzo, J., Carpenter, T. O., Coffin, J. D., and Hurley, M. M. (2010) Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J. Biol. Chem. 285, 2834-2846
11. Xiao, L., Esliger, A., and Hurley, M. M. (2013) Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J. Bone Miner. Res. 28, 35-45
12. Lu, Y., and Feng, J. Q. (2011) FGF23 in skeletal modeling and remodeling. Curr. Osteoporos. Rep. 9, 103-108
13. Yu, X., and White, K. E. (2005) Review FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 16, 221-232
14. Quarles, L. D. (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276-286
15. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M. C., Moe, O. W., and Kuro-o, M. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281, 6120-6123
16. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., and Yamashita, T. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774
17. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., Iwasaki, H., Iida, A., Shiraki-Iida, T., Nishikawa, S., Nagai, R., and Nabeshima, Y. I. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390, 45-51
18. Jüppner, H. (2011) Phosphate and FGF-23. Kidney Int. Supp. 79(S121), S24-S27
19. Masuda, M., Yamamoto, H., Kozai, M., Tanaka, S., Ishiguro, M., Takei, Y., Nakahashi, O., Ikeda, S., Uebanso, T., Taketani, Y., Segawa, H., Miyamoto, K., and Takeda, E. (2010) Regulation of renal sodium-dependent phosphate co-transporter genes (Npt2a and Npt2c) by all-trans-retinoic acid and its receptors. Biochem. J. 429, 583-592
20. Sapir-Koren, R., and Livshits, G. (2011) Bone mineralization and regulation of phosphate homeostasis. IBMS BoneKey 8, 286-300
21. Wang, H., Yoshiko, Y., Yamamoto, R., Minamizaki, T., Kozai, K., Tanne, K., Aubin, J. E., and Maeda, N. (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J. Bone Miner. Res. 23, 939-948
22. Touriol, C., Bornes, S., Bonnal, S., Audigier, S., Prats, H., Prats, A. C., and Vagner, S. (2003) Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons. Biol. Cell 95, 169-178
23. Beck, L., Soumounou, Y., Martel, J., Krishnamurthy, G., Gauthier, C., Goodyer, C. G., and Tenenhouse, H. S. (1997) Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J. Clin. Invest. 99, 1200-1209
24. Lorenz-Depiereux, B., Bastepe, M., Benet-Pagès, A., Amyere, M., Wagenstaller, J., Müller-Barth, U., Badenhoop, K., Kaiser, S. M., Rittmaster, R. S., Shlossberg, A. H., Olivares, J. L., Loris, C., Ramos, F. J., Glorieux, F., Vikkula, M., Jüppner, H., and Strom, T. M. (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38, 1248-1250
25. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Jüppner, H., and Jonsson, K. B. (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145, 3087-3094
26. Rowe, P. (2012) Regulation of bone-renal mineral and energy metabolism: The PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit. Rev. Eukaryot. Gene Expr. 22, 61-86
27. Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J. Q., and Quarles, L. D. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 25, 2551-2562
28. Zebboudj, A. F., Imura, M., and Boström, K. (2002) Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J. Biol. Chem. 277, 4388-4394
29. Azhar, M., Yin, M., Zhou, M., Li, H., Mustafa, M., Nusayr, E., Keenan, J. B., Chen, H., Pawlosky, S., Gard, C., Grisham, C., Sanford, L. P., and Doetschman, T. (2009) Gene targeted ablation of high molecular weight fibroblast growth factor-2. Dev. Dyn. 238, 351-357
30. Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J. D., and Hurley, M. M. (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 105, 1085-1093
31. Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595-610
32. Sims, N. A., Clément-Lacroix, P., Da Ponte, F., Bouali, Y., Binart, N., Moriggl, R., Goffin, V., Coschigano, K., Gaillard-Kelly, M., Kopchick, J., Baron, R., and Kelly, P. A. (2000) Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J. Clin. Invest. 106, 1095-1103
33. Pfaffl, M. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
34. Butler, J. S., Murray, D. W., Hurson, C. J., O'Brien, J., Doran, P. P., and O'Byrne, J. M. (2011) The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density. J. Orthop. Res. 29, 414-418
35. Edwin, F., Anderson, K., Ying, C., and Patel, T. B. (2009) Intermolecular interactions of sprouty proteins and their implications in development and disease. Mol. Pharmacol. 76, 679-691
36. Ammann, P., and Rizzoli, R. (2003) Bone strength and its determinants. Osteopor. Int. 14, S13-S18
37. Stachowiak, M. K., Fang, X., Myers, J. M., Dunham, S. M., Berezney, R., Maher, P. A., and Stachowiak, E. K. (2003) Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forward-and-gate" signaling module that controls cell growth and differentiation. J. Cell. Biochem. 90, 662-691
38. Atkins, G. J., Rowe, P. S., Lim, H. P., Welldon, K. J., Ormsby, R., Wijenayaka, A. R., Zelenchuk, L., Evdokiou, A., and Findlay, D. M. (2011) Sclersotin is locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res. 26, 1425-1436
39. He, G., Dahl, T., Veis, A., and George, A. (2003) Nucleation of apatite crystals in vitro by self-assembled dentin matrix protein 1. Nat. Mater. 2, 552-558
40. Kumar, J., Swanberg, M., McGuigan, F., Callreus, M., Gerdhem, P., and Akesson, K. (2011) LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways. Bone 49, 343-348
41. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., Townsend, R. R., Feldman, H. I., St John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G. S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J. A., Moe, O. W., Kuro-O, M., Kusek, J. W., Keane, M. G., and Wolf, M. (2011) FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408
42. Hurley, M. M., Tetradis, S., Huang, Y. F., Hock, J., Kream, B. E., Raisz, L. G., and Sabbieti, M. G. (1999) Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J. Bone Miner. Res. 14, 776-783
43. Xiao, L., Sobue, T., Esliger, A., Kronenberg, M. S., Coffin, J. D., Doetschman, T., and Hurley, M. M. (2010) Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone 47, 360-370
44. Liao, S., Bodmer, J. R., Azhar, M., Newman, G., Coffin, J. D., Doetschman, T., and Schultz Jel, J. (2010) The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 48, 1245-1254
45. Kardami, E., Jiang, Z. S., Jimenez, S. K., Hirst, C. J., Sheikh, F., Zahradka, P., and Cattini, P. A. (2004) Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc. Res. 63, 458-466